Cytokinetics Inc
CYTK36.290USD
-0.400-1.09%
交易中 （美東）報價延遲15分鐘
4.33B總市值
虧損本益比TTM
關於 Cytokinetics Inc 公司
Cytokinetics, Incorporated 是一家後期專業心血管生物製藥公司，專注於發現、開發和商業化肌肉生物學導向的候選藥物，作爲治療心肌功能受損的衰弱性疾病的潛在療法。該公司致力於心臟肌球蛋白抑制劑 aficamten 的商業化，並正在對阻塞性和非阻塞性肥厚性心肌病患者進行額外的臨牀試驗評估。該公司還在開發心臟肌球蛋白激活劑 omecamtiv mecarbil，用於治療射血分數嚴重降低 (HFrEF) 的心力衰竭患者；CK-586，一種心臟肌球蛋白抑制劑，可用於治療射血分數保留的心力衰竭 (HFpEF)；CK-089，一種快速骨骼肌肌鈣蛋白激活劑，可用於治療特定類型的肌營養不良症和其他骨骼肌功能受損的情況。
公司簡介
公司代碼CYTK
公司名稱Cytokinetics Inc
上市日期Apr 29, 2004
CEOMr. Robert I. Blum
員工數量498
證券類型Ordinary Share
年結日Apr 29
公司地址350 Oyster Point Boulevard
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94080
電話16506243000
網址https://cytokinetics.com/
公司代碼CYTK
上市日期Apr 29, 2004
CEOMr. Robert I. Blum
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Robert I. Blum
Mr. Robert I. Blum
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
229.51K
-6.13%
Dr. Fady Ibraham Malik, M.D., Ph.D.
Dr. Fady Ibraham Malik, M.D., Ph.D.
Executive Vice President - Research and Development
Executive Vice President - Research and Development
77.01K
--
Dr. John T. Henderson, M.D.
Dr. John T. Henderson, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
69.01K
+0.82%
Dr. Wendell Wierenga, Ph.D.
Dr. Wendell Wierenga, Ph.D.
Independent Director
Independent Director
26.83K
+0.62%
Ms. Nancy J. Wysenski
Ms. Nancy J. Wysenski
Independent Director
Independent Director
25.26K
+0.65%
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Independent Director
Independent Director
24.56K
+1.35%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
17.91K
+48.87%
Mr. Robert E. (Bob) Landry
Mr. Robert E. (Bob) Landry
Independent Director
Independent Director
7.33K
--
Ms. Diane Weiser
Ms. Diane Weiser
Investors Relations
Investors Relations
--
--
Dr. Robert A Harrington, M.D.
Dr. Robert A Harrington, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Robert I. Blum
Mr. Robert I. Blum
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
229.51K
-6.13%
Dr. Fady Ibraham Malik, M.D., Ph.D.
Dr. Fady Ibraham Malik, M.D., Ph.D.
Executive Vice President - Research and Development
Executive Vice President - Research and Development
77.01K
--
Dr. John T. Henderson, M.D.
Dr. John T. Henderson, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
69.01K
+0.82%
Dr. Wendell Wierenga, Ph.D.
Dr. Wendell Wierenga, Ph.D.
Independent Director
Independent Director
26.83K
+0.62%
Ms. Nancy J. Wysenski
Ms. Nancy J. Wysenski
Independent Director
Independent Director
25.26K
+0.65%
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Independent Director
Independent Director
24.56K
+1.35%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
11.69%
T. Rowe Price Investment Management, Inc.
11.24%
The Vanguard Group, Inc.
9.90%
Wellington Management Company, LLP
6.69%
Fidelity Management & Research Company LLC
6.38%
Other
54.11%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
11.69%
T. Rowe Price Investment Management, Inc.
11.24%
The Vanguard Group, Inc.
9.90%
Wellington Management Company, LLP
6.69%
Fidelity Management & Research Company LLC
6.38%
Other
54.11%
股東類型
持股股東
佔比
Investment Advisor
59.12%
Investment Advisor/Hedge Fund
37.54%
Hedge Fund
13.26%
Research Firm
4.93%
Private Equity
2.08%
Pension Fund
1.79%
Sovereign Wealth Fund
0.83%
Bank and Trust
0.76%
Individual Investor
0.71%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
769
145.68M
121.98%
-6.27M
2025Q1
797
140.59M
117.75%
-12.63M
2024Q4
779
136.46M
115.26%
-16.24M
2024Q3
771
140.16M
119.20%
-8.76M
2024Q2
761
139.65M
120.41%
+11.58M
2024Q1
733
121.60M
116.11%
-3.04M
2023Q4
661
118.12M
120.45%
-1.38M
2023Q3
589
114.14M
118.93%
-7.33M
2023Q2
585
113.47M
118.68%
-8.63M
2023Q1
579
113.58M
118.87%
-6.12M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
13.96M
11.69%
-54.58K
-0.39%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
13.42M
11.24%
+3.46M
+34.80%
Apr 30, 2025
The Vanguard Group, Inc.
11.82M
9.9%
-67.91K
-0.57%
Mar 31, 2025
Wellington Management Company, LLP
7.99M
6.69%
+100.04K
+1.27%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.62M
6.38%
-1.15M
-13.09%
Mar 31, 2025
State Street Global Advisors (US)
6.09M
5.1%
-82.34K
-1.34%
Mar 31, 2025
Deep Track Capital LP
3.07M
2.57%
+573.85K
+22.95%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.94M
2.46%
+96.15K
+3.38%
Mar 31, 2025
RTW Investments L.P.
2.72M
2.28%
--
--
Mar 31, 2025
Fidelity Institutional Asset Management
2.70M
2.26%
+668.11K
+32.88%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ALPS Medical Breakthroughs ETF
2.67%
Tema Heart & Health ETF
1.51%
SPDR S&P Biotech ETF
1.42%
Virtus LifeSci Biotech Clinical Trials ETF
0.9%
Direxion Daily S&P Biotech Bull 3X Shares
0.81%
NYLI Healthy Hearts ETF
0.52%
T Rowe Price Capital Appreciation Equity ETF
0.51%
Invesco Nasdaq Biotechnology ETF
0.44%
ProShares Ultra Nasdaq Biotechnology
0.44%
Harbor Health Care ETF
0.42%
查看更多
ALPS Medical Breakthroughs ETF
佔比2.67%
Tema Heart & Health ETF
佔比1.51%
SPDR S&P Biotech ETF
佔比1.42%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.9%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.81%
NYLI Healthy Hearts ETF
佔比0.52%
T Rowe Price Capital Appreciation Equity ETF
佔比0.51%
Invesco Nasdaq Biotechnology ETF
佔比0.44%
ProShares Ultra Nasdaq Biotechnology
佔比0.44%
Harbor Health Care ETF
佔比0.42%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
